Apellis Pharmaceuticals Inc
(STU:1JK)
€
25.73
-0.175 (-0.68%)
Market Cap: 3.15 Bil
Enterprise Value: 3.25 Bil
PE Ratio: 0
PB Ratio: 12.89
GF Score: 25/100 Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022 / 04:20PM GMT
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
Alright. Thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. We could not be more pleased to have the team from Apellis Pharmaceuticals with us today. Telling us about the story, I mean, pretty slow, nothing's really going on for you guys these days, right, just filling out. Kidding, obviously, this is really -- this is like the important time for the company. So we're really excited you guys join us today.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you, Madhu.
Questions & Answers
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
Awesome. So let's start with a discussion of your kind of major C3 drug pegcetacoplan, I'm going to call it PEG for short, in geographic atrophy, also known as GA. So start by kind of walking through at a kind of high level, the mechanistic rationale for targeting
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot